NCT00997399View on ClinicalTrials.gov

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Advanced Solid Tumors
Interventions
DRUG

panobinostat (LBH589)

Trial Locations (5)

9007

Novartis Investigative Site, Sankt Gallen

84103

University of Utah / Huntsman Cancer Institute, Salt Lake City

2300 RC

Novartis Investigative Site, Leiden

3584CX

Novartis Investigative Site, Utrecht

L63 4JY

Novartis Investigative Site, Merseyside

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY